Biodesix Prepares to Test Thousands as Students Return to Campus
BOULDER, CO, August 12, 2020 – Biodesix, Inc., a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24. “The health and safety of our nation’s students, and the faculty and staff that teach, guide, and mentor them, is of utmost importance to us. We are pleased to be able to support CSU in their efforts to help navigate a return to campus during this global pandemic,” said Scott Hutton, CEO of Biodesix.
“The health and safety of our nation’s students, and the faculty and staff that teach, guide, and mentor them, is of utmost importance to us. We are pleased to be able to support CSU in their efforts to help navigate a return to campus during this global pandemic,” said Scott Hutton, CEO of Biodesix.
“We understand that timely results are critical, and are proud that our tests with their rapid time to results are a part of this important plan.” The Biodesix SARS-CoV-2 ddPCR™ Test, which was released in partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), detects SARS-CoV-2 (the virus that causes COVID19) and earned Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration earlier this year. Since April, Biodesix has processed more than 40,000 tests with results delivered in 24-48 hours.
About
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit www.biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.